Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,599
  • Shares Outstanding, K 49,146
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,040 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.55
  • Price/Sales 313.39
  • Price/Cash Flow N/A
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 363.91% (-37.76%)
  • Historical Volatility 55.25%
  • IV Percentile 83%
  • IV Rank 28.58%
  • IV High 874.01% on 05/15/25
  • IV Low 159.78% on 02/14/25
  • Expected Move (DTE 10) 1.0880 (65.94%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 130
  • Open Int (30-Day) 90
  • Expected Range 0.5620 to 2.7380

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +1,665,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4300 +14.36%
on 01/14/26
1.9150 -14.60%
on 01/26/26
+0.1154 (+7.59%)
since 01/09/26
3-Month
1.2300 +32.96%
on 12/26/25
1.9150 -14.60%
on 01/26/26
+0.2254 (+15.99%)
since 11/10/25
52-Week
1.1300 +44.73%
on 04/07/25
2.0400 -19.83%
on 02/14/25
-0.2346 (-12.55%)
since 02/10/25

Most Recent Stories

More News
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)
2026 New Year’s Greetings from the CEO

LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code...

MNOV : 1.6400 (unch)
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)
Message from the CEO to MediciNova Shareholders

LA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis , I would like to provide additional...

MNOV : 1.6400 (unch)
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)
MediciNova: Q3 Earnings Snapshot

MediciNova: Q3 Earnings Snapshot

MNOV : 1.6400 (unch)
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.6400 (unch)

Business Summary

MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies,...

See More

Key Turning Points

3rd Resistance Point 1.7350
2nd Resistance Point 1.7000
1st Resistance Point 1.6700
Last Price 1.6400
1st Support Level 1.6050
2nd Support Level 1.5700
3rd Support Level 1.5400

See More

52-Week High 2.0400
Fibonacci 61.8% 1.6924
Last Price 1.6400
Fibonacci 50% 1.5850
Fibonacci 38.2% 1.4776
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar